What are the National Comprehensive Cancer Network (NCCN) preferred regimens for systemic therapy in renal cell carcinoma (RCC)?

Updated: Feb 19, 2021
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print

The National Comprehensive Cancer Network (NCCN) currently recommends that for relapsed or stage IV clear cell kidney cancer, preferred first-line regimens for systemic therapy in favorable-risk patients are as follows [19] :

  • Pazopanib
  • Sunitinib
  • Axitinib + pembrolizumab
  • Cabozantinib + nivolumab

NCCN recommendations for poor-risk or intermediate-risk patients are as follows:

  • Ipilimumab + nivolumab(category 1)
  • Axitinib + pembrolizumab (category 1)
  • Cabozantinib + nivolumab
  • Cabozantinib

For subsequent therapy, preferred category 1 regimens are cabozantinib or nivolumab. For relapsed or stage IV non–clear cell kidney cancer, the NCCN recommends participation in a clinical trial. Sunitinib is the only preferred regimen.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!